Faced with generic competition to big-selling drugs, Eli Lilly (LLY) plans to cut 3,500 jobs — or 8.5 percent of its global workforce – in hopes of saving $500 million annually.

Most of the cuts will occur in the U.S. through a voluntary early retirement program, although layoffs will take place as facilities are closed, such as research and development centers in Shanghai, China, and Bridgewater, N.J. Lilly currently employs about 41,000 people worldwide.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • 1) Lechleiter picked the right time to quit.

    2) Put all your eggs in the AZ basket and you see the result.

    3) Fret not, Lilyputians, you will get a great package. My wife’s severance was actually more than my salary when benefits were included. Hopefully you will get some free ducats to the Lily Corporate Center cafeteria. Best coffee in pharma.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy